TGFB1 and neoplasm: Our results confirmed the notion that disrupting tumor hypoxia is beneficial for ICB mediated immunotherapy,[18, 19, 23, 24, 27] as exemplified with reduced MDSCs, M2 TAMs, Treg, TGF‐β, and IL‐10 and strengthened CTLs (Figure 5) and Tem (Figures 5 and 6).